A MOFs nanoscale enzyme and application thereof in detection of new coronavirus
By modifying the CD147 protein on the surface of MOF nanozymes and utilizing its specific binding to the novel coronavirus, a label-free colorimetric detection method is achieved by catalyzing chromogenic molecules. This solves the sensitivity and equipment limitations of novel coronavirus detection and enables rapid, visualized, and highly sensitive detection.
Patent Information
- Application Number
- CN202211008677.0
- Authority / Receiving Office
- CN · China
- Patent Type
- Patents(China)
- Current Assignee / Owner
- Filing Date
- 2022-08-22
- Publication Date
- 2026-05-08
- Estimated Expiration
- 2042-08-22
AI Technical Summary
Existing COVID-19 testing methods lack sensitivity and specificity, and the equipment is expensive and inflexible, making it difficult to achieve large-scale, multi-sample testing. Enzymes are easily inactivated under harsh conditions, limiting the application of colorimetric methods.
MOF nanozymes are used to modify the surface of CD147 protein by forming a MOF material with metal ions and terephthalic acid. The MOF material is then modified with its peroxidase-like properties to catalyze the colorimetric molecules TMB, ABTS, OPD and PPD. Combined with the specific binding of CD147 to the SARS-CoV-2 virus, label-free, rapid and highly sensitive colorimetric detection is achieved.
It enables rapid, visualized, and highly sensitive detection of SARS-CoV-2, with a detection limit as low as 3 PFU/mL, simplifying the detection process, reducing costs, and making it suitable for operation in remote areas.